Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010–2025
This study characterizes the clinical spectrum, time-to-onset patterns, and risk factors of sipuleucel-T-associated CVAEs, providing essential pharmacovigilance data for managing patients with mCRPC.
Authors
- Linlin Wang (ORCID: https://orcid.org/0000-0001-9332-284X)
- Wensheng Liu (ORCID: https://orcid.org/0000-0003-4357-1893)
- Lu Han (ORCID: https://orcid.org/0000-0002-9198-6455)
- Xue Song
- Qiong Du
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1716090
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00